Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data

Unconventional use of injectable long-acting cabotegravir and rilpivirine against HIV-1 in PWH in clinical need: 52 weeks real-world data

Abstract Background Long-acting Cabotegravir and Rilpivirine (LA CAB + RPV) shows potential advantages in heavily comorbid and even in viremic people with HIV (PWH). We assessed LA CAB + RPV durability in a cohort of PWH with a high comorbidity burden and adherence issues. Methods Retrospective obse...

Full description

Saved in:
Bibliographic Details
Main Authors: Valentina Iannone, Roberto Rossotti, Nicholas Brian Bana, Gabriele Cavazza, Federico D’Amico, Francesca Lombardi, Pierluigi Francesco Salvo, Gianmaria Baldin, Simona Di Giambenedetto, Dario Bernacchia, Gabriele Pagani, Alberto Borghetti, Stefano Rusconi
Format: Article
Language:English
Published: BMC 2025-01-01
Series:BMC Infectious Diseases
Subjects:
Long acting antiretrovirals
Population in need
Comorbidities
Adherence issues
Virological suppression
Online Access:https://doi.org/10.1186/s12879-025-10499-0
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doi.org/10.1186/s12879-025-10499-0

Similar Items